Shots:

• Deep Genomics will receive an undisclosed upfront payment and is eligible to receive development milestones- BioMarin will receive an exclusive option to obtain Deep Genomics’ rights to each program for development & commercialization
• Deep Genomics will use its AI drug discovery platform (The AI workbench) to identify & validate target mechanisms- lead candidates & BioMarin will advance them into preclinical & clinical development
• AI workbench enables rapid exploration of novel targetable mechanisms & therapeutic candidates- it combines deep learning- automation- advanced biomedical knowledge & massive amounts of in vitro & in vivo data to accurately identify targetable molecular mechanisms & guide the discovery & development of oligonucleotide therapies

 ­ Ref: BioMarin | Image: BioMarin